The Compounding Crackdown: What Happened to Compounded Semaglutide and Where Things Stand in 2026

Q: Is compounded semaglutide still legal in 2026?

The legal status of compounded semaglutide in 2026 is unsettled and depends on the pharmacy type and the basis for compounding. FDA removed Ozempic and Wegovy from its drug shortage list in early 2025, ending the drug shortage exception that was the primary legal basis for most compounded semaglutide — particularly from 503B outsourcing facilities. For 503A pharmacies, some legal arguments remain available around patient-specific individualization, but these are contested and subject to ongoing litigation. The regulatory landscape has shifted multiple times, and patients should verify current status with their prescriber and pharmacy rather than relying on any static summary.

Q: What is the drug shortage exception that allowed compounded GLP-1 medications?

Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FDCA), compounding pharmacies are generally prohibited from producing 'essentially a copy' of a commercially available FDA-approved drug. However, both sections provide an exception when a drug appears on the FDA's official drug shortage list. When FDA places a drug on the shortage list, the copy prohibition is lifted and licensed compounders may produce versions of that drug. This exception applied to semaglutide and tirzepatide when Ozempic, Wegovy, Mounjaro, and Zepbound appeared on the shortage list beginning in 2022, creating the legal basis for the compounded GLP-1 market. Once FDA determines a shortage is resolved and removes the drug from the list, the exception no longer applies.

Q: What is the difference between a 503A and 503B compounding pharmacy?

503A pharmacies are traditional compounding pharmacies licensed by state pharmacy boards. They must have a valid patient-specific prescription before compounding. They are not required to meet FDA current Good Manufacturing Practice (cGMP) standards and are not subject to regular FDA inspections. 503B outsourcing facilities are a category created by the Drug Quality and Security Act of 2013 (DQSA). They voluntarily register with the FDA, must comply with cGMP standards, are subject to regular FDA inspections, and can compound larger batches without patient-specific prescriptions. 503B is generally the higher quality tier. For patients, the pharmacy's designation (503A vs. 503B) is one of the most important quality indicators for compounded medication.

Q: Why did the FDA end the semaglutide drug shortage designation?

FDA determined in early 2025 that an adequate supply of semaglutide — specifically Ozempic and Wegovy — was available from Novo Nordisk to meet patient demand. Under the FDCA's drug shortage framework, FDA's determination that supply is adequate is the legal trigger for removal from the shortage list. The decision was contested: critics argued that 'adequate supply' should account for affordability, not just volume — that a drug priced at $1,000–$1,300 per month is not truly accessible to most of the patient population that needs it, even if Novo Nordisk has sufficient manufacturing capacity. FDA's position was that the shortage framework addresses supply, not price access. This access-versus-supply distinction is one of the central open legal and policy questions in the compounding litigation.

Q: Is compounded tirzepatide still available in 2026?

As of May 2026, tirzepatide (Mounjaro/Zepbound) has remained on the FDA drug shortage list longer than semaglutide, providing continued legal basis for compounding through both 503A pharmacies and 503B outsourcing facilities. Compounded tirzepatide programs have been more stable in 2025–2026 as a result. However, this stability is contingent on tirzepatide's continued shortage list status, which can change when FDA determines that adequate supply is available. Patients and prescribers using compounded tirzepatide should monitor FDA's drug shortage list and understand that the legal basis for these programs may change. Always verify current shortage status at the time you seek or renew a prescription.

Contents

Why This Matters
The Legal Foundation: What Is Pharmaceutical Compounding?
The Drug Shortage Exception
What Changed: The FDA's Shortage Determinations
The Base vs. Salt Controversy
The Legal Challenges
Tirzepatide: A Different Timeline
What This Means for Patients
The Open Policy Questions
Frequently Asked Questions

Update — June 2026: Since this guide was written, the FDA has declared shortages of both semaglutide and tirzepatide resolved. The legal crackdown this guide analyzed is now substantially complete — most mass-market compounded GLP-1 programs have ended or are ending. This guide remains valuable as legal background. For current consumer action steps, see: Your Compounded GLP-1 Program Is Ending: What to Do Now →

Key Regulatory Events

2022

FDA adds semaglutide to drug shortage list

Ozempic supply failures as existing diabetes patients compete with a surging wave of new weight-loss demand. The shortage exception opens the legal basis for compounding.
2022–2024

Compounded GLP-1 market expands rapidly

503A pharmacies and 503B outsourcing facilities begin compounding semaglutide and tirzepatide. Telehealth platforms emerge offering compounded GLP-1s at roughly 1/4 to 1/3 of brand-name cost, serving millions of patients with valid prescriptions.
Late 2023

Tirzepatide added to shortage list

Mounjaro and Zepbound join the shortage list as Eli Lilly struggles to meet explosive demand. Legal basis for compounded tirzepatide established.
Early 2025

FDA removes semaglutide from drug shortage list

FDA finds adequate supply of Ozempic and Wegovy available. The shortage exception for semaglutide compounding ends. Compliance deadlines set for 503B facilities. The access-versus-supply legal dispute intensifies.
2025

Legal challenges filed; base vs. salt dispute surfaces

Compounding pharmacies and industry groups challenge FDA's shortage determination under the APA. Separately, FDA issues guidance on semaglutide salt forms; compounders contest the position. Courts issue varying rulings.
May 2026

Legal landscape unsettled; tirzepatide shortage list continues

Semaglutide compounding availability has narrowed significantly. Multiple cases remain in litigation. Tirzepatide remains on the shortage list. Regulatory status for both drugs continues to evolve.

1. Why This Matters

For roughly two to three years, compounded GLP-1 medications represented the most accessible medically supervised path to semaglutide and tirzepatide for millions of Americans. The brand-name versions — Ozempic, Wegovy, Mounjaro, Zepbound — were priced beyond reach for most patients without insurance coverage, and that coverage was itself unreliable and difficult to obtain. Compounded alternatives, dispensed through telehealth platforms with valid prescriptions from licensed providers, offered the same active ingredient at a fraction of the cost.

Then, beginning in 2025, that path became legally contested — and for many patients, it closed.

Understanding what happened requires understanding a specific corner of federal pharmaceutical law: the compounding framework and the drug shortage exception that sits at its center. This is not abstract regulatory history. The decisions FDA made, the legal arguments compounders advanced, and the courts' responses have had direct consequences for patients — for how much they pay, what they can access, and what happens when the rules change mid-treatment.

This guide explains the legal framework, what FDA did and why, how the industry responded, and where things stand as of May 2026. It does not give legal advice, and it does not predict outcomes in pending litigation. What it does is lay out what the law says, what happened, and what the open questions are.

2. The Legal Foundation: What Is Pharmaceutical Compounding?

Pharmaceutical compounding is the practice of creating customized medications outside the standard drug manufacturing and approval system. A compounding pharmacy takes pharmaceutical-grade active ingredients and formulates them into a specific dosage form for a patient — a particular concentration, a particular delivery mechanism, a particular combination of ingredients — when a commercially available product does not or cannot meet that patient's specific need.

Compounding has a legitimate and longstanding history in pharmacy practice. Before industrial pharmaceutical manufacturing, nearly all medications were compounded by the local pharmacist. Today, compounding serves real clinical needs: a patient who cannot swallow tablets needs a liquid formulation; a pediatric patient needs a dose not available commercially; a patient has an allergy to a standard inactive ingredient and needs a customized preparation.

The federal legal framework governing compounding is found primarily in the Federal Food, Drug, and Cosmetic Act (FDCA), as substantially amended by the Drug Quality and Security Act of 2013 (DQSA). The DQSA created two distinct regulatory pathways for compounding, each with different requirements and oversight structures.

Legal Term

503A — Traditional Compounding Pharmacy

Under Section 503A of the FDCA, traditional compounding pharmacies may compound drugs for individual patients pursuant to valid, patient-specific prescriptions. 503A pharmacies are regulated primarily by state pharmacy boards, not the FDA. They are not subject to federal current Good Manufacturing Practice (cGMP) standards. They cannot compound drugs in anticipation of general demand — the prescription must precede the compounding. And critically: they cannot compound a drug that is "essentially a copy" of a commercially available approved drug, unless an exception applies.

Legal Term

503B — Outsourcing Facility

Section 503B, created by the DQSA in 2013, established a higher-tier voluntary registration pathway for compounding facilities that want to operate at greater scale. 503B outsourcing facilities register with the FDA, are subject to regular FDA inspection, must comply with current Good Manufacturing Practice (cGMP) standards, and may produce larger batches without patient-specific prescriptions — distributing compounded drugs to healthcare facilities and prescribers. The 503B framework represents meaningfully stronger federal oversight than the 503A pathway. A public list of registered 503B facilities is maintained by the FDA and is publicly verifiable.

Legal Term

DQSA — Drug Quality and Security Act (2013)

Enacted in the aftermath of a 2012 fungal meningitis outbreak that killed more than 60 people and injured hundreds — caused by contaminated compounded medications from a pharmacy operating far outside appropriate standards — the DQSA was Congress's response to the inadequacy of the existing federal compounding oversight framework. It created the 503B outsourcing facility pathway, clarified FDA's authority over compounding, and strengthened the prohibition on compounding copies of commercially available drugs.

The key limitation common to both 503A and 503B: they cannot compound a drug that is "essentially a copy" of a commercially available FDA-approved drug. This prohibition is the foundation of the entire legal dispute over GLP-1 compounding. Ozempic, Wegovy, Mounjaro, and Zepbound are commercially available FDA-approved drugs. A compounded semaglutide preparation is, on its face, a copy. But the copy prohibition has exceptions — and one of those exceptions changed everything.

Feature	503A Pharmacy	503B Outsourcing Facility
Primary regulator	State pharmacy board	FDA (federal)
Prescription requirement	Valid patient-specific Rx required before compounding	Rx required for patient dispensing; not required for batch production
cGMP standards	No federal cGMP requirement	Required — must comply with FDA cGMP
FDA inspections	Limited FDA oversight; state-level primary	Regular FDA inspections; public warning letter record
Production scale	Limited; patient-specific batches	Larger batches permitted for distribution to healthcare facilities
Public registry	No federal public registry	Yes — FDA maintains verifiable public list
Quality consistency	Highly variable by state and facility	More consistent; federally audited under cGMP

3. The Drug Shortage Exception

Both Section 503A and Section 503B contain a statutory exception to the copy prohibition: compounders may produce drugs that appear on FDA's current drug shortage list. This is the provision that made the compounded GLP-1 market legally possible.

Legal Term

Drug Shortage Exception (503A / 503B)

Under the FDCA, both 503A pharmacies and 503B outsourcing facilities may compound a drug that appears on FDA's official drug shortage list, even if that drug is commercially available, provided all other applicable requirements are met. The exception is grounded in a straightforward public health rationale: if patients cannot obtain an approved drug because supply is inadequate to meet clinical demand, the competitive and safety policy reasons for prohibiting compounded copies give way to the patient access interest. The exception persists only as long as the drug remains on the shortage list.

Semaglutide — the active ingredient in Ozempic and Wegovy — appeared on FDA's drug shortage list beginning in 2022. The cause was structural: Novo Nordisk's manufacturing capacity had been calibrated to supply an existing diabetes patient population, and it was completely unprepared for the scale of demand that materialized when semaglutide's weight-loss effects became widely known. Patients who needed Ozempic to manage type 2 diabetes were competing for supply with a massive and rapidly growing population seeking the medication for obesity management. Shortages were real and documented.

Tirzepatide — the active ingredient in Mounjaro and Zepbound — joined the shortage list in late 2023 as Eli Lilly faced similar supply challenges.

With both drugs on the shortage list, licensed compounders operating within the applicable legal framework had a clear statutory basis for their activity. 503A pharmacies could compound semaglutide and tirzepatide for individual patients pursuant to valid prescriptions. 503B facilities could produce larger batches for distribution to prescribers and healthcare facilities. Telehealth platforms built programs around these compounded alternatives, offering medically supervised access at roughly a quarter to a third of brand-name prices.

The result was significant: millions of Americans who could not access Ozempic, Wegovy, Mounjaro, or Zepbound at their commercial prices — and who lacked or were denied insurance coverage — obtained the same active pharmaceutical ingredient through a legally grounded compounding pathway. This was not a gray-market workaround. It was a statutory exception functioning as designed.

The legal basis matters The drug shortage exception was the primary — not the sole, but the primary — legal foundation for most compounded GLP-1 production, particularly from 503B outsourcing facilities. When FDA's shortage determinations changed, the legal foundation shifted with them. Understanding this dependency explains why so much changed so quickly for so many patients.

4. What Changed: The FDA's Shortage Determinations

FDA makes drug shortage determinations based on its assessment of whether supply is adequate to meet demand. When FDA concludes that a shortage has resolved — that the commercial market can supply patients' needs — it removes the drug from the shortage list. At that point, the statutory basis for the shortage exception ends.

In early 2025, FDA removed semaglutide from the drug shortage list, concluding that Novo Nordisk's supply of Ozempic and Wegovy had become adequate to meet patient demand. FDA set compliance deadlines for compounders to wind down semaglutide compounding under the shortage exception. For 503B outsourcing facilities, the deadline was hard: once the exception expired, bulk compounding of semaglutide copies was no longer lawful.

The FDA's determination triggered immediate controversy on a question the shortage framework had not previously been required to answer with such high stakes: what does "adequate supply" mean?

The Access Argument: Supply Is Not the Same as Access

Patients, providers, advocacy organizations, and compounding pharmacies raised a pointed objection to FDA's shortage resolution finding: a drug priced at $1,000 to $1,300 per month — which Ozempic and Wegovy were, absent insurance coverage or manufacturer savings programs — is not "adequately supplied" in any meaningful sense for the patients who need it but cannot afford it.

The argument has both factual and legal dimensions. On the facts: the same supply constraints that drove patients to compounding in the first place — inadequate insurance coverage, manufacturer pricing, limited access to savings programs — continued to exist after Novo Nordisk's manufacturing capacity caught up with demand. From the perspective of a patient who earns $60,000 a year and lacks employer coverage for obesity medications, a drug available at $1,300 per month is not functionally available.

On the law: the question is whether FDA's shortage determination framework requires the agency to consider affordability — not just volume — in assessing whether "adequate supply" exists. The FDCA's shortage provisions do not explicitly define "adequate supply" to include or exclude affordability considerations. This statutory ambiguity became one of the central legal arguments in the challenges that followed.

FDA's position, as reflected in its shortage determination, was that the shortage framework addresses supply — the availability of the drug in commerce — not the pricing or insurance coverage conditions that affect whether individual patients can obtain it. Affordability, FDA's reasoning went, is a separate policy problem that the shortage exception is not designed to solve. It is a substantial legal and policy argument; it is also one that millions of patients experiencing the functional consequences of "resolved" shortage status found difficult to accept.

The central legal and policy tension Access is not the same as supply. A drug can be available in commercial quantities and still be inaccessible to most of the population that needs it. Whether FDA's shortage determination framework is required to account for affordability — and whether courts will enforce that requirement — is one of the genuinely open legal questions in this space.

5. The Base vs. Salt Controversy

Parallel to the shortage determination dispute, a separate legal and scientific argument emerged from within the compounding industry — one that attempted to establish an alternative legal basis for semaglutide compounding that did not depend on the shortage exception at all.

Ozempic and Wegovy use semaglutide in its base form. Some compounding pharmacies and their active pharmaceutical ingredient suppliers were sourcing and using semaglutide sodium — a salt form of semaglutide in which the semaglutide molecule is associated with a sodium counterion. The argument compounders advanced: semaglutide sodium is a chemically distinct compound from base semaglutide. Since it is not the same compound as the active ingredient in Ozempic or Wegovy, it cannot be a "copy" of those products even after the shortage list removal. The prohibition does not apply.

FDA rejected this argument explicitly. The agency's position rests on a well-established principle in pharmaceutical regulation: a drug and its salt forms are treated as the same active ingredient for purposes of drug approval, labeling, and regulatory classification. The same principle that allows a generic manufacturer to produce a salt form of a drug without treating it as a new active ingredient — the same principle that lets pharmacists substitute between salt and base forms under therapeutic equivalence — means that semaglutide and semaglutide sodium are the same active ingredient under FDA's regulatory framework. The copy prohibition attaches to the active ingredient, not to the specific salt form.

Compounders and their legal advocates disputed this framing. They argued that the active ingredient in a finished drug product is the specific molecular entity in that product — not a class of chemically related compounds. On this reading, a preparation using semaglutide sodium as its active ingredient is not a copy of a preparation using semaglutide base, because the active ingredients are chemically distinct.

Courts have been asked to resolve this dispute as part of the broader compounding litigation. As of May 2026, the legal question remains contested, and FDA's enforcement posture continues to treat semaglutide sodium as the same active ingredient as semaglutide for purposes of the copy prohibition.

What this means practically If a compounding platform represents that it uses "semaglutide sodium" or "semaglutide acetate" to distinguish its formulation from the Ozempic/Wegovy prohibition, understand that FDA has explicitly rejected this as a valid basis for continued compounding. Whether that position will ultimately be sustained in litigation is a separate question, but patients relying on this distinction as their program's legal basis are in contested territory.

→ Related: Semaglutide Base vs. Acetate/Sodium Salt: The Science, the FDA's Position, and the Compounders' Argument — a deeper dive into the chemistry question that became central to the legal dispute.

6. The Legal Challenges

The FDA's shortage determination and subsequent enforcement actions against compounders did not go unchallenged. Several compounding pharmacies and industry groups filed legal challenges in federal court, invoking a range of administrative law doctrines.

Administrative Procedure Act Challenges

The primary legal vehicle was the Administrative Procedure Act (APA), which allows courts to review agency action that is "arbitrary and capricious." Under the APA's arbitrary-and-capricious standard, an agency must engage in reasoned decisionmaking — it cannot disregard relevant factors, rely on improper considerations, or reach a conclusion that is not rationally connected to the evidence before it. Challengers argued that FDA's shortage determination was arbitrary and capricious because:

FDA failed to adequately account for the access and affordability dimensions of "adequate supply" in making its shortage determination;
FDA's enforcement timeline gave patients insufficient transition time to shift to alternatives that, for many, did not exist at comparable cost;
FDA's guidance on the salt-form issue departed from prior agency practice without adequate explanation;
FDA's enforcement posture conflated the legally distinct 503A and 503B frameworks in ways that exceeded its statutory authority.

The Litigation Landscape as of May 2026

The legal proceedings have not followed a single, linear trajectory. Different cases in different courts have produced different results. Some courts granted preliminary injunctive relief, temporarily halting FDA enforcement against specific compounders while the underlying legal questions were briefed and argued. Others declined to issue such relief. Some courts have addressed the APA challenge on the merits; others have been focused on threshold procedural questions. The overall picture as of May 2026 is a landscape in which:

Multiple cases remain pending in various stages of litigation;
No binding appellate resolution has settled the core legal questions;
The practical availability of compounded semaglutide has varied significantly depending on the current procedural posture of relevant cases — in some periods, court orders have temporarily maintained access that FDA's enforcement would otherwise have ended;
The legal uncertainty has itself been a dominant experience for patients and platforms, with rules that seemed settled being unsettled by new court orders or regulatory guidance.

The practical consequence: uncertainty Patients on compounded semaglutide programs over the past year have experienced whiplash. Programs that appeared to have a clear legal basis found that basis challenged. Court orders that temporarily maintained access expired or were overturned. Platforms wound down their semaglutide programs, sometimes with short notice. For patients mid-treatment — who had found a medication that was working and built a clinical regimen around it — the instability was not abstract. It was a practical disruption with health consequences.

Any summary of "where things stand" on compounded semaglutide as of a specific date is subject to change. Readers should verify current legal status with their prescriber, their pharmacy, and if relevant, with legal counsel before making decisions. This guide reflects the state of publicly available information as of May 2026.

7. Tirzepatide: A Different Timeline

Tirzepatide — the active ingredient in Mounjaro and Zepbound — has had a different regulatory trajectory than semaglutide, and that difference matters significantly for patients seeking compounded GLP-1 options in 2026.

As of the time of writing, tirzepatide remains on FDA's drug shortage list. Mounjaro and Zepbound have not been removed from shortage status as semaglutide products were. While tirzepatide remains on the list, the drug shortage exception continues to provide legal basis for compounding by both 503A pharmacies and 503B outsourcing facilities. Compounded tirzepatide programs have been meaningfully more stable than compounded semaglutide programs over the 2025–2026 period.

Several factors have contributed to tirzepatide's longer shortage status. Eli Lilly's manufacturing scale-up for Mounjaro and Zepbound faced its own constraints. The patient population on tirzepatide therapy has grown rapidly. The supply-demand gap for tirzepatide has been slower to close than for semaglutide.

The contingent nature of this stability

It bears stating clearly: the continued availability of compounded tirzepatide is not an established long-term condition. It is contingent on tirzepatide's shortage list status, which can change when FDA determines that adequate supply exists. The same analytical framework that governed semaglutide — including the contested access-versus-supply debate, the salt-form questions, and the enforcement timeline issues — applies equally to tirzepatide. If and when FDA removes tirzepatide from the shortage list, the same legal dynamics will play out.

FDA has shown awareness of the tirzepatide compounding space and has issued guidance in this area. Patients and prescribers using compounded tirzepatide should not assume that current stability represents a permanent condition. The appropriate approach is to stay current with FDA shortage list determinations, understand that the legal basis for your program depends on that status, and have contingency plans.

Verify current tirzepatide shortage status FDA's drug shortage database is publicly accessible at accessdata.fda.gov/scripts/drugshortages. The status of any given drug can change with a new FDA determination. Availability that exists today may not exist in three to six months.

8. What This Means for Patients

The legal complexity described in this guide has direct, practical consequences for patients. Here is how to think about your situation depending on where you currently stand.

If you were using compounded semaglutide

Your program's current legal status depends on the regulatory state as of the time you are reading this — which has changed multiple times and may have changed since this guide was written. The appropriate steps are to contact your platform and your prescriber to understand the current basis for your program, whether your pharmacy is continuing to compound semaglutide and on what legal authority, and what your options are if that basis is no longer available. Do not assume that what was true three months ago remains true today.

If you are considering starting a compounded GLP-1 program

Ask your provider directly: What is the current legal basis for this program? Which pharmacy will fill my prescription, and what is its regulatory status (503A or 503B)? Is the drug you plan to compound currently on the FDA shortage list? What happens to my access if that changes? A provider and pharmacy who cannot answer these questions clearly are not in a position to provide you with the informed basis for a treatment decision.

If compounded options are unavailable or uncertain

The remaining medically supervised access pathways for GLP-1 medications are manufacturer savings programs (available to commercially insured patients who meet eligibility requirements), patient assistance programs (for uninsured or underinsured patients who meet income criteria), insurance coverage navigation (prior authorization, appeals, employer plan advocacy), and telehealth programs offering brand-name medications with savings card integration. None of these are as accessible as compounded pricing for most patients, which is precisely the gap the compounding market was filling.

The research peptide gray market

A direct consequence of the compounding crackdown is the growth of the unregulated "research peptide" market — suppliers selling semaglutide and tirzepatide labeled for laboratory use only, without any of the legal, clinical, or quality frameworks that governed compounding pharmacy programs. This market exists in significant part because the regulatory closure of the compounding window pushed patients out of a supervised access pathway with nowhere else to go. The line between the FDA's compounding enforcement and the growth of an unregulated parallel market is not hypothetical — it is a direct causal relationship that anyone analyzing this space honestly must acknowledge.

→ Related: The Mochi Health State Pharmacy Investigation: What Patients Should Know — a case study in how the compounding crackdown context has intersected with platform-level billing and regulatory issues.

9. The Open Policy Questions

Open Questions — Not Conclusions

What Courts and Policymakers Are Confronting

The following questions do not have settled legal or policy answers. They represent the genuinely contested issues at the center of this regulatory dispute. They are worth naming not because this guide can resolve them, but because understanding what is actually at stake clarifies what the legal and policy debate is about.

Question 1 Should "adequate supply" in FDA drug shortage determinations include affordability, not just volume? If a drug is commercially available at a price that is inaccessible to most of the patient population that needs it, has the shortage truly been resolved?

Question 2 Should Medicare and Medicaid coverage of GLP-1 medications for obesity be a prerequisite — or at minimum a relevant factor — before FDA ends the shortage exception? Is it coherent policy to declare a shortage resolved when the primary federal health insurance programs for low-income and elderly Americans do not cover the drug for most indications?

Question 3 Does the compounding framework's patient-protection intent — ensuring access to necessary medications that are unavailable, unavailable in the right form, or unavailable at accessible cost — require a different analysis when the commercially available product is priced out of reach for most of the intended patient population?

Question 4 How should courts apply the APA's arbitrary-and-capricious standard to FDA shortage determinations that affect millions of patients and a multi-billion-dollar market? Is the access-versus-supply argument within the range of factors FDA was required to consider under existing statutory authority, or does it require a legislative fix?

Question 5 What is the regulatory and public health cost of pushing patients out of supervised compounding programs and into the unregulated research peptide market? Is there a framework under which access to compounded GLP-1 medications could be maintained under meaningful quality oversight even after shortage list removal, and if so, what would it look like?

These questions are before courts and, in some form, before Congress and FDA's own rulemaking processes. This guide takes no position on how they should be resolved. The purpose of naming them is to make clear that the legal dispute over compounded GLP-1 medications is not merely a technical regulatory matter — it raises fundamental questions about how U.S. pharmaceutical law should balance drug safety, market exclusivity, patient access, and affordability.

Frequently Asked Questions

Is compounded semaglutide still legal in 2026?

The legal status is unsettled and has changed multiple times. FDA removed Ozempic and Wegovy from the drug shortage list in early 2025, ending the primary legal basis for compounded semaglutide from 503B outsourcing facilities. For 503A pharmacies, some legal arguments remain available under patient-specific individualization grounds, but these are contested and subject to ongoing litigation. Court orders have at various points temporarily restored or restricted availability. Patients should verify current status with their prescriber and pharmacy — no static summary can reliably capture where this stands at any given time.

What is the drug shortage exception that allowed compounded GLP-1 medications?

Sections 503A and 503B of the FDCA generally prohibit compounders from producing essentially a copy of a commercially available FDA-approved drug. Both sections provide an exception when a drug is on FDA's official drug shortage list. When Ozempic, Wegovy, Mounjaro, and Zepbound appeared on the shortage list beginning in 2022, this exception provided licensed compounders with a clear statutory basis for producing compounded versions. The exception ends when FDA removes a drug from the shortage list — a determination the agency made for semaglutide in early 2025.

What is the difference between a 503A and 503B compounding pharmacy?

503A pharmacies are traditional compounding pharmacies regulated primarily by state pharmacy boards. They must have a valid, patient-specific prescription before compounding and are not subject to federal cGMP standards. 503B outsourcing facilities were created by the DQSA in 2013; they voluntarily register with FDA, must comply with cGMP standards, and are subject to regular FDA inspections. 503B facilities can produce larger batches without patient-specific prescriptions. For patients evaluating a compounding program, the pharmacy's 503A or 503B designation is one of the most important quality indicators — it is publicly verifiable through FDA's registry.

Why did the FDA end the semaglutide drug shortage designation?

FDA determined that Novo Nordisk had achieved sufficient manufacturing capacity to supply Ozempic and Wegovy to meet patient demand — that is, that the volume-of-supply problem that originally caused the shortage had been resolved. The decision was contested by compounders and patient advocates who argued that "adequate supply" should account for affordability, not just volume — that a drug priced at $1,000–$1,300 per month is not functionally available to most patients who need it even if supply exists. FDA's position was that the shortage framework addresses supply, not pricing. This access-versus-supply debate is one of the central open questions in the ongoing litigation.

Is compounded tirzepatide still available in 2026?

As of May 2026, tirzepatide remains on FDA's drug shortage list, and compounded tirzepatide programs continue to operate with a clearer legal basis than compounded semaglutide programs. Both 503A pharmacies and 503B outsourcing facilities can legally compound tirzepatide while it remains on the shortage list. However, this availability is contingent on tirzepatide's continued shortage status, which FDA can change. The same legal framework that ended compounded semaglutide availability will apply to tirzepatide if and when FDA determines the tirzepatide shortage is resolved. Patients should verify current shortage list status before starting or renewing a compounded tirzepatide program.

Disclaimer: This article is written by a California attorney for general informational and educational purposes only. It does not constitute legal advice and does not create an attorney-client relationship. The regulatory landscape for pharmaceutical compounding is actively evolving — the information in this guide reflects publicly available information as of May 2026 and may not reflect subsequent regulatory, judicial, or legislative changes. Always verify current legal status with a licensed attorney, your prescriber, and your pharmacy before making decisions. BetterNewLives.com is not affiliated with any compounding pharmacy, telehealth platform, pharmaceutical manufacturer, or regulatory body.